



---

Kristin Baltrusaitis, MA

Mauricio Santillana, PhD

John Brownstein, PhD

Adam Crawley, MPH



---

## Representativeness of FNY Participants

# Representativeness of FNY Participants

- Goal: Compare the FNY population to the US population, quantify the participation biases of FNY, identify under-represented populations and guide recruitment targeting
- Methods:
  - Summarize social and demographic characteristics of FNY participants (users and household members)
    - Gender, age group, and SES (using HDI as proxy)
  - Use chi-square tests and Kolmogorov-Smirnov tests to compare these characteristics to the target population

f

n

f

# Flu Season 2014-2015



FL: 00000 0014 0015

0014

Total number of Participants= 49,814

—

—

—

—

—

—

—

—


—

—

—

—

# Gender




Chi-Square Test:

$\chi^2 = 1946.8$ ,  $df=1$ ,  $p < 0.00001$

\* A larger proportion of females participated to the study, with respect to the baseline value



# Distribution of Age Groups




Chi-Square Test:

$\chi^2 = 13048.75$ ,  $df=7$ ,  $p < 0.00001$

\* All age classes were represented in the sample, however, a significant difference between the repartition in age of active participants and U.S. population is observed

# Health Development Index as SES Proxy (by county)



Two-sample Kolmogorov-Smirnov Test:

$D=0.6304$   $p<0.0001$

\*The distributions of HDI is significantly different for FNY participants and US population



---

## Social and Demographic Characteristics of Respondent Users

# Characteristics of “Good” Users


- Goal: Determine the demographical and behavioral characteristics that are associated with the response rate of FNY participants.
- Methods:
  - User:
    - completed at least one survey 3 weeks prior to the end of flu season
    - between the ages of 13 and 80
    - complete information
  - “Good” user:
    - completed more than 3 surveys
  - Model used:
    - Multivariable logistic regression

# Characteristics Assessed



Variable	Description
Gender	Male; Female
Age Group	13-29; 30-39; 40-49; 50-59; 60-69; 70-79
ILI Status at First Survey	Reported ILI as defined by CDC (fever with cough and/or sore throat) <sup>1</sup> at first survey; did not report ILI at first survey
Household Members	Reported for at least one other household member; did not report for other household members
Health Development Index	Continuous Scale 1-10, 1 indicating low SES, 10 indicating high SES

# Gender



**Table 1:** Frequencies of Gender by Follow-up


	Male	Female	Total
<b>Good</b>	3551 (40.2%)	7320 (33.4%)	10871 (35.4%)
<b>Bad</b>	5272 (59.8%)	14594 (66.6%)	19866 (64.6%)
<b>Total</b>	8823 (28.7%)	21914 (71.3%)	30737

**Table 2:** ORs of Good Follow-up for Gender by year

Year	OR	LCI	UCI	p
2014-2015	0.75*	0.71	0.79	<0.0001
2013- 2014	1.06	1.00	1.12	0.046
2012- 2013	1.02	0.94	1.11	0.634

\*Females are less likely to be good reporters compared to males

# Age Group



**Table 1: Frequencies of Age Group by Follow-up**

	13-30	30-40	40-50	50-60	60-70	70-80
Good	900 (28.2%)	1239 (26.2%)	1767 (31.8%)	2979 (39.0%)	3110 (41.3%)	876 (42.0%)
Bad	2297 (71.8%)	3495 (73.8%)	3785 (68.2%)	4658 (61.0%)	4421 (58.7%)	1210 (58.0%)
Total	3197 (10.4%)	4734 (15.4%)	5552 (18.1%)	7637 (24.8%)	7531 (24.5%)	2086 (6.8%)

**Table 2: ORs of Good Follow-up for Age Group**

	13-30	30-40	40-50	50-60	60-70	70-80
OR	0.67	0.54	0.70	REF	1.14	1.23
p	<0.0001	<0.0001	<0.0001	REF	0.0001	<0.0001

\*Older users are more likely to be better responders than younger users

# HDI



**Table 1:** Descriptive Statistics for HDI

Statistic	Value
Min	0
Median	5.025
Max	9.535
IQR	4.36-6.01


**Table 2:** OR of Good Follow-up per unit increase in HDI

OR	LCI	UCI	p
1.12*	1.09	1.14	<0.0001

\*For each unit increase in HDI the odds of being a good reporter increases



# ILI Status at First Entry



**Table 1:** Frequencies of ILI Status at First Entry by Follow-up


Follow	ILI status	
	Yes	No
Good	297 (11.9%)	10574 (37.5%)
Bad	2206 (82.1%)	17660 (62.5%)
<b>Total</b>	<b>2503</b> <b>(8.14%)</b>	<b>28234</b> <b>(91.9%)</b>

**Table 2:** ORs of Good Follow-up for ILI Status at First Entry

Characteristic	OR	LCI	UCI	p
ILI status at first entry	0.22*	0.19	0.25	<0.0001

\*Individuals who report ILI at the first entry are less likely to be good reporters compared to those who do not report ILI at first entry

# Multiple Household Members



**Table 1:** Frequencies of Users Who Report for Other Household Members by Follow-up

Follow	Reports for Household Members	
	Yes	No
<b>Good</b>	5312 (52.9%)	4734 (22.9%)
<b>Bad</b>	5559 (47.1%)	15132 (77.1%)
<b>Total</b>	10046 (32.7%)	20691 (67.3%)

**Table 2:** ORs of Good Follow-up for Users Who Report for Other Household Members

Characteristic	OR	LCI	UCI	p
Multiple Household members	3.29*	3.12	3.346	<0.0001

\*Individuals who report for other household members are more likely to be good reporters compared to those who do not report for other members

# Summary of Results



Variable	OR (p-value)
ILI Status at 1 <sup>st</sup> Survey (yes)	0.22 (<0.0001)
Household Members (yes)	3.29 (<0.0001)
Health Development Index	1.12 (<0.0001)
Gender (Females)	0.75 (<0.0001)
Age Group (70-80)	1.23 (<0.0001)
(60-70)	1.14 (0.0001)
(40-50)	0.70 (<0.0001)
(30-40)	0.54 (<0.0001)
(13-30)	0.67 (<0.0001)

# Sensitivity Analysis

## Definitions of “Good” User:

>10: More than 10 entries submitted

>03: More than 3 entries submitted

>01: More than 1 entry submitted



---

## Ongoing Projects

# Vaccination Assessment

- Goal: Assess vaccination of cohorts over time in order to measure vaccine field effectiveness.
- Methods:
  - Assess vaccine effectiveness by using unadjusted vaccine effective rate equations

# Unadjusted Vaccine Effectiveness



- **Vaccine Effectiveness:**

$$VE = 100 \times (1 - \text{Relative Risk})$$
$$= 100 \times \left( 1 - \frac{\text{ILI rate in vaccinated group}}{\text{ILI rate in unvaccinated group}} \right)$$

- 2012-2013:

$$VE = 100 \times \left( 1 - \frac{2690/22473}{1703/12743} \right) = 10.4\%$$

- 2013-2014:

$$VE = 100 \times \left( 1 - \frac{2010/16533}{1487/9623} \right) = 21.3\%$$

- 2014-2015:

$$VE = 100 \times \left( 1 - \frac{4341/27024}{4043/18793} \right) = 25.3\%$$

# Vaccine Effectiveness



<b>Year</b>	<b>CDC (overall VE estimate – adjusted*)</b>	<b>FNY (VE estimate - unadjusted)</b>
2012-2013	49% (43% to 55%)	10.4%
2013-2014	51% (43% to 58%)	21.3%
2014-2015	23% (14%– 31%)	25.3%

\*Estimates are typically adjusted for study site, age, sex, underlying medical conditions, and days from illness onset to enrollment



# FNY used as a predictor for ILI at the regional level

- Goal: Use FNY data to provide real-time information to estimate ILI activity in the US at the regional level

